Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Blockbusters No One Talks About

Executive Summary

Drugs like Nexium, Lipitor, Lovenox and Plavix lost patent protection years ago, but continue to generate blockbuster level sales. Here's a look at the blockbuster brands that have stood the test of (generic) time.

You may also be interested in...



Crestor Generics To Launch After 12-Day Delay

AstraZeneca's legal gambit results in almost two more weeks of sales for the statin even though the court ultimately agreed with FDA on labeling carve-out for orphan indication.

FDA approval of generic Lovenox sparks debate and lawsuit

The US FDA approval of the first generic version of Sanofi-Aventis's Lovenox (enoxaparin sodium) to Novartis' generics arm Sandoz, which uses technology from Momenta Pharmaceuticals, has caused a buzz because the agency has treated the application like a standard but yet complicated ANDA and did not require full clinical studies.

Takeda’s High-Dose TYK2 Data Could Set It Apart In Psoriasis

Safety and efficacy data show that as long as Takeda can execute effectively on a Phase III program for TAK-279, the company should be well positioned in the oral psoriasis market.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB001835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel